The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $13.15

Today's change0.00 0.00%
Updated December 19 4:03 PM EST. Delayed by at least 15 minutes.
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $13.15

Today's change0.00 0.00%
Updated December 19 4:03 PM EST. Delayed by at least 15 minutes.

Boston Scientific Corp closed at (U.S.)$13.15.

Over the last five days, shares have gained 1.15% and 9.40% year to date. Shares have performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $13.15
  • High--
  • Low--
  • Bid / Ask(U.S.) $13.14 / (U.S.) $13.36
  • YTD % change+9.40%
  • Volume0
  • Average volume (10-day)14,672,384
  • Average volume (1-month)12,392,343
  • Average volume (3-month)12,760,201
  • 52-week range(U.S.) $11.10 to (U.S.) $14.08
  • Beta1.05
  • Trailing P/E60.84×
  • P/E 1 year forward15.94×
  • Forward PEG1.52×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.22
Updated December 19 4:03 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+3.93%

Based on its net profit margin of 3.93%, Boston Scientific Corp is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue1,8461,8731,7741,838
Total other revenue--------
Total revenue1,8461,8731,7741,838
Gross profit1,3051,3141,2391,282
Total cost of revenue541559535556
Total operating expense1,7821,9421,5771,712
Selling / general / administrative735737660717
Research & development212206191217
Depreciation / amortization109109109105
Interest expense (income), net operating--------
Unusual expense (income)1643064292
Other operating expenses, total21254025
Operating income64-69197126
Interest income (expense), net non-operating-54-53-54-58
Gain (loss) on sale of assets--------
Other--------
Income before tax3-10414659
Income after tax434133108
Income tax, total-40-10813-49
Net income434133108
Total adjustments to net income--------
Net income before extra. items434133108
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items434133108
Inc. avail. to common incl. extra. items434133108
Diluted net income434135108
Dilution adjustment----20
Diluted weighted average shares1,3481,3451,3491,329
Diluted EPS excluding extraordinary itemsvalue per share0.030.000.100.08
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share0.110.150.120.13